2018 Q1 Form 10-K Financial Statement
#000156459018006216 Filed on March 19, 2018
Income Statement
| Concept | 2018 Q1 | 2017 | 2016 Q4 |
|---|---|---|---|
| Revenue | $10.00K | $1.018M | $70.00K |
| YoY Change | -96.3% | 154.5% | -36.36% |
| Cost Of Revenue | |||
| YoY Change | |||
| Gross Profit | |||
| YoY Change | |||
| Gross Profit Margin | |||
| Selling, General & Admin | $2.910M | $9.990M | $2.180M |
| YoY Change | 22.27% | 7.88% | -28.05% |
| % of Gross Profit | |||
| Research & Development | $3.771M | $12.85M | $3.110M |
| YoY Change | 82.97% | 11.18% | 75.71% |
| % of Gross Profit | |||
| Depreciation & Amortization | $33.00K | $173.0K | $100.0K |
| YoY Change | -31.25% | -55.53% | 0.0% |
| % of Gross Profit | |||
| Operating Expenses | $6.685M | $22.84M | $5.290M |
| YoY Change | 50.5% | 9.72% | 10.35% |
| Operating Profit | -$6.679M | -$21.82M | |
| YoY Change | 60.13% | 6.88% | |
| Interest Expense | $285.0K | $215.0K | $40.00K |
| YoY Change | 1576.47% | -82.66% | -108.89% |
| % of Operating Profit | |||
| Other Income/Expense, Net | $1.468M | -$1.000K | |
| YoY Change | 9075.0% | -101.16% | |
| Pretax Income | -$5.040M | -$21.56M | -$3.750M |
| YoY Change | 21.74% | 27.2% | -26.9% |
| Income Tax | $0.00 | ||
| % Of Pretax Income | |||
| Net Earnings | -$5.042M | -$21.56M | -$3.750M |
| YoY Change | 21.85% | 27.24% | -26.89% |
| Net Earnings / Revenue | -50420.0% | -2117.98% | -5357.14% |
| Basic Earnings Per Share | |||
| Diluted Earnings Per Share | -$560.6K | -$6.304M | -$4.688M |
| COMMON SHARES | |||
| Basic Shares Outstanding | 11.89M | 12.03M | |
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2018 Q1 | 2017 | 2016 Q4 |
|---|---|---|---|
| SHORT-TERM ASSETS | |||
| Cash & Short-Term Investments | $143.5M | $32.40M | $17.10M |
| YoY Change | 889.66% | 89.47% | -47.38% |
| Cash & Equivalents | $126.6M | $14.50M | $10.26M |
| Short-Term Investments | $17.00M | $18.00M | $6.800M |
| Other Short-Term Assets | $1.900M | $6.600M | $20.50M |
| YoY Change | -86.13% | -67.8% | -42.58% |
| Inventory | |||
| Prepaid Expenses | |||
| Receivables | $0.00 | $0.00 | |
| Other Receivables | $0.00 | $0.00 | |
| Total Short-Term Assets | $145.4M | $39.10M | $37.52M |
| YoY Change | 409.53% | 4.27% | -45.38% |
| LONG-TERM ASSETS | |||
| Property, Plant & Equipment | $300.0K | $300.0K | $444.0K |
| YoY Change | -24.81% | -25.0% | -36.39% |
| Goodwill | |||
| YoY Change | |||
| Intangibles | |||
| YoY Change | |||
| Long-Term Investments | |||
| YoY Change | |||
| Other Assets | $100.0K | $100.0K | $100.0K |
| YoY Change | 0.0% | 0.0% | 0.0% |
| Total Long-Term Assets | $500.0K | $400.0K | $569.0K |
| YoY Change | -4.58% | -33.33% | -30.86% |
| TOTAL ASSETS | |||
| Total Short-Term Assets | $145.4M | $39.10M | $37.52M |
| Total Long-Term Assets | $500.0K | $400.0K | $569.0K |
| Total Assets | $145.9M | $39.50M | $38.09M |
| YoY Change | 402.06% | 3.67% | -45.21% |
| SHORT-TERM LIABILITIES | |||
| YoY Change | |||
| Accounts Payable | $1.400M | $700.0K | $837.0K |
| YoY Change | 55.73% | -12.5% | -10.86% |
| Accrued Expenses | $1.500M | $2.700M | $1.400M |
| YoY Change | 7.14% | 92.86% | -6.67% |
| Deferred Revenue | |||
| YoY Change | |||
| Short-Term Debt | $0.00 | $5.100M | $19.40M |
| YoY Change | -100.0% | -73.71% | -42.43% |
| Long-Term Debt Due | |||
| YoY Change | |||
| Total Short-Term Liabilities | $2.900M | $8.700M | $21.97M |
| YoY Change | -80.95% | -60.45% | -41.82% |
| LONG-TERM LIABILITIES | |||
| Long-Term Debt | $0.00 | $0.00 | $0.00 |
| YoY Change | |||
| Other Long-Term Liabilities | $100.0K | $0.00 | $100.0K |
| YoY Change | -100.0% | -66.67% | |
| Total Long-Term Liabilities | $100.0K | $0.00 | $100.0K |
| YoY Change | -100.0% | -66.67% | |
| TOTAL LIABILITIES | |||
| Total Short-Term Liabilities | $2.900M | $8.700M | $21.97M |
| Total Long-Term Liabilities | $100.0K | $0.00 | $100.0K |
| Total Liabilities | $3.035M | $8.700M | $22.02M |
| YoY Change | -80.06% | -60.45% | -42.2% |
| SHAREHOLDERS EQUITY | |||
| Retained Earnings | -$178.3M | -$148.0M | |
| YoY Change | 17.23% | 12.93% | |
| Common Stock | $12.00K | $1.000K | |
| YoY Change | 500.0% | 0.0% | |
| Preferred Stock | |||
| YoY Change | |||
| Treasury Stock (at cost) | |||
| YoY Change | |||
| Treasury Stock Shares | |||
| Shareholders Equity | $142.9M | $30.80M | $16.07M |
| YoY Change | |||
| Total Liabilities & Shareholders Equity | $145.9M | $39.50M | $38.09M |
| YoY Change | 402.02% | 3.67% | -45.21% |
Cashflow Statement
| Concept | 2018 Q1 | 2017 | 2016 Q4 |
|---|---|---|---|
| OPERATING ACTIVITIES | |||
| Net Income | -$5.042M | -$21.56M | -$3.750M |
| YoY Change | 21.85% | 27.24% | -26.89% |
| Depreciation, Depletion And Amortization | $33.00K | $173.0K | $100.0K |
| YoY Change | -31.25% | -55.53% | 0.0% |
| Cash From Operating Activities | -$5.107M | -$19.94M | -$5.000M |
| YoY Change | 18.77% | 7.78% | -1.96% |
| INVESTING ACTIVITIES | |||
| Capital Expenditures | $198.0K | $23.00K | -$200.0K |
| YoY Change | 6500.0% | -95.09% | 100.0% |
| Acquisitions | |||
| YoY Change | |||
| Other Investing Activities | $1.000M | -$11.20M | $6.000M |
| YoY Change | -85.29% | 1300.0% | -45.45% |
| Cash From Investing Activities | $803.0K | -$11.20M | $5.800M |
| YoY Change | -88.19% | 761.15% | -47.27% |
| FINANCING ACTIVITIES | |||
| Cash Dividend Paid | |||
| YoY Change | |||
| Common Stock Issuance & Retirement, Net | $106.8M | $5.336M | |
| YoY Change | 5893.27% | 456.99% | |
| Debt Paid & Issued, Net | |||
| YoY Change | |||
| Cash From Financing Activities | 111.2M | 21.08M | 0.000 |
| YoY Change | -2324.48% | 2242.44% | -100.0% |
| NET CHANGE | |||
| Cash From Operating Activities | -5.107M | -19.94M | -5.000M |
| Cash From Investing Activities | 803.0K | -11.20M | 5.800M |
| Cash From Financing Activities | 111.2M | 21.08M | 0.000 |
| Net Change In Cash | 106.9M | -10.05M | 800.0K |
| YoY Change | -4439.29% | -46.81% | -86.89% |
| FREE CASH FLOW | |||
| Cash From Operating Activities | -$5.107M | -$19.94M | -$5.000M |
| Capital Expenditures | $198.0K | $23.00K | -$200.0K |
| Free Cash Flow | -$5.305M | -$19.96M | -$4.800M |
| YoY Change | 23.29% | 5.25% | -4.0% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2016 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P3Y11M4D | |
| CY2017 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P9Y2M1D | |
| CY2016 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
389000 | |
| CY2017 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
351000 | |
| CY2016 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-956000 | |
| CY2016 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
635000 | |
| CY2018Q1 | dei |
Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
|
11893644 | |
| CY2017Q2 | dei |
Entity Public Float
EntityPublicFloat
|
22438884 | |
| CY2017Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
14472000 | |
| CY2017Q4 | us-gaap |
Short Term Investments
ShortTermInvestments
|
17971000 | |
| CY2017Q4 | us-gaap |
Restricted Cash Current
RestrictedCashCurrent
|
5333000 | |
| CY2016Q4 | us-gaap |
Restricted Cash Current
RestrictedCashCurrent
|
19468000 | |
| CY2017Q4 | us-gaap |
Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
|
37638000 | |
| CY2016Q4 | us-gaap |
Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
|
36551000 | |
| CY2016 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
14706 | |
| CY2016Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
140990 | |
| CY2017 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
742000 | |
| CY2017 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
61108 | |
| CY2017Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
|
354886 | |
| CY2015Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
147.45 | |
| CY2016 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
23.70 | |
| CY2016 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
|
64.95 | |
| CY2016 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-102000 | |
| CY2017 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-7000 | |
| CY2017 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-90000 | |
| CY2017 | us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
1287000 | |
| CY2016 | us-gaap |
Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
|
-60000 | |
| CY2017 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
863000 | |
| CY2016Q4 | us-gaap |
Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
|
805000 | |
| CY2016Q4 | us-gaap |
Deferred Rent Credit Current
DeferredRentCreditCurrent
|
41000 | |
| CY2016Q4 | us-gaap |
Assets
Assets
|
38090000 | |
| CY2016Q4 | us-gaap |
Accounts Payable Current
AccountsPayableCurrent
|
837000 | |
| CY2016Q4 | us-gaap |
Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
|
596000 | |
| CY2017Q4 | us-gaap |
Liabilities Current
LiabilitiesCurrent
|
8739000 | |
| CY2017 | cbio |
Stock Issued During Period Value Common Stock Upon Exercise Of Warrants
StockIssuedDuringPeriodValueCommonStockUponExerciseOfWarrants
|
1817000 | |
| CY2016Q4 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
1539000 | |
| CY2016 | us-gaap |
Operating Expenses
OperatingExpenses
|
20817000 | |
| CY2017 | us-gaap |
Operating Expenses
OperatingExpenses
|
22840000 | |
| CY2017 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-21822000 | |
| CY2016 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
11555000 | |
| CY2017 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
9993000 | |
| CY2017 | us-gaap |
Research And Development Expense
ResearchAndDevelopmentExpense
|
12847000 | |
| CY2016 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
9262000 | |
| CY2016 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-20418000 | |
| CY2017 | cbio |
Interest And Other Income Expense Net
InterestAndOtherIncomeExpenseNet
|
261000 | |
| CY2016 | cbio |
Interest And Other Income Expense Net
InterestAndOtherIncomeExpenseNet
|
3473000 | |
| CY2017 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-21561000 | |
| CY2016 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-16945000 | |
| CY2017 | us-gaap |
Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
|
3951000 | |
| CY2017 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-25512000 | |
| CY2016 | us-gaap |
Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
|
-16945000 | |
| CY2017 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-7.45 | |
| CY2016 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-21.75 | |
| CY2017 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
3423901 | |
| CY2016 | us-gaap |
Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
|
779166 | |
| CY2017 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
1000 | |
| CY2016 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
-2000 | |
| CY2017 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-21560000 | |
| CY2016 | us-gaap |
Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
|
-16947000 | |
| CY2015Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
31425000 | |
| CY2016 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
635000 | |
| CY2016 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
957000 | |
| CY2017 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
863000 | |
| CY2017 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
173000 | |
| CY2017 | us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
-118000 | |
| CY2017 | us-gaap |
Increase Decrease In Prepaid Rent
IncreaseDecreaseInPrepaidRent
|
40000 | |
| CY2016 | us-gaap |
Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
|
10002000 | |
| CY2016 | cbio |
Noncash Or Part Noncash Unrealized Gain Loss On Investments
NoncashOrPartNoncashUnrealizedGainLossOnInvestments
|
-2000 | |
| CY2017 | cbio |
Stock Issued During Period Value Common Stock For Follow On Offering Net Of Issuance Costs
StockIssuedDuringPeriodValueCommonStockForFollowOnOfferingNetOfIssuanceCosts
|
9684000 | |
| CY2016 | us-gaap |
Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
|
1000 | |
| CY2017 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
5336000 | |
| CY2017 | cbio |
Stock Issued During Period Value Convertible Preferred Stock Common Stock And Warrants For Follow On Offering Net Of Issuance Costs
StockIssuedDuringPeriodValueConvertiblePreferredStockCommonStockAndWarrantsForFollowOnOfferingNetOfIssuanceCosts
|
18563000 | |
| CY2017 | us-gaap |
Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
|
-18000 | |
| CY2017Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
3680 | |
| CY2016Q4 | us-gaap |
Preferred Stock Shares Issued
PreferredStockSharesIssued
|
0 | |
| CY2017Q4 | us-gaap |
Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
|
3680 | |
| CY2017Q4 | us-gaap |
Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
|
0.001 | |
| CY2017Q4 | us-gaap |
Common Stock Shares Authorized
CommonStockSharesAuthorized
|
100000000 | |
| CY2017Q4 | us-gaap |
Common Stock Shares Issued
CommonStockSharesIssued
|
6081230 | |
| CY2017Q4 | us-gaap |
Common Stock Shares Outstanding
CommonStockSharesOutstanding
|
6081230 | |
| CY2017 | us-gaap |
Contracts Revenue
ContractsRevenue
|
1018000 | |
| CY2016Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
5000000 | |
| CY2016Q4 | us-gaap |
Assets Current
AssetsCurrent
|
37521000 | |
| CY2016Q4 | us-gaap |
Restricted Cash Noncurrent
RestrictedCashNoncurrent
|
125000 | |
| CY2017Q4 | us-gaap |
Deposits Assets Noncurrent
DepositsAssetsNoncurrent
|
128000 | |
| CY2016Q4 | us-gaap |
Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
|
444000 | |
| CY2016Q4 | us-gaap |
Deferred Revenue Current
DeferredRevenueCurrent
|
283000 | |
| CY2016Q4 | us-gaap |
Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
|
19403000 | |
| CY2016Q4 | us-gaap |
Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
|
47000 | |
| CY2016Q4 | us-gaap |
Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
|
7000 | |
| CY2017Q4 | us-gaap |
Liabilities
Liabilities
|
8739000 | |
| CY2016Q4 | us-gaap |
Liabilities
Liabilities
|
22019000 | |
| CY2017Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
||
| CY2016Q4 | us-gaap |
Preferred Stock Value
PreferredStockValue
|
||
| CY2017Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
6000 | |
| CY2016Q4 | us-gaap |
Common Stock Value
CommonStockValue
|
1000 | |
| CY2017Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
204262000 | |
| CY2016Q4 | us-gaap |
Additional Paid In Capital
AdditionalPaidInCapital
|
164053000 | |
| CY2016Q4 | us-gaap |
Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
|
-1000 | |
| CY2017Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-173494000 | |
| CY2016Q4 | us-gaap |
Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
|
-147982000 | |
| CY2017Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
30774000 | |
| CY2016Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
16071000 | |
| CY2017Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
39513000 | |
| CY2016Q4 | us-gaap |
Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
|
38090000 | |
| CY2017Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
| CY2016Q4 | us-gaap |
Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
|
0.001 | |
| CY2017Q4 | us-gaap |
Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
|
5000000 | |
| CY2017 | us-gaap |
Proceeds From Sale Maturity And Collection Of Shortterm Investments
ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
|
14300000 | |
| CY2017 | us-gaap |
Nature Of Operations
NatureOfOperations
|
<div> <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td valign="top" style="width:5.24%;white-space:nowrap"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Nature of Operations</p></td></tr></table></div> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Catalyst Biosciences, Inc. and its subsidiary (the “Company” or “Catalyst”) is a clinical-stage biotechnology company focused on developing novel medicines to address hematology indications, including the treatment of hemophilia. Its facilities are in South San Francisco, California and it operates in one segment. Prior to August 20, 2015, the name of the Company was Targacept, Inc. (“Targacept”). On August 20, 2015, Targacept completed its business combination with Catalyst (the “Merger”).</p> <p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Liquidity<font style="font-weight:normal;"> </font></p> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company had a net loss of $21.6 million for the year ended December 31, 2017 and an accumulated deficit of $173.5 million as of December 31, 2017 and expects to continue to incur losses for the next several years. As of December 31, 2017, the Company had $32.4 million in cash, cash equivalents and short-term investments and used $20.0 million of cash in operating activities for the year ended December 31, 2017. Management believes that the currently available resources, including cash, cash equivalents and short-term investments, will provide sufficient funds to enable the Company to meet its operating plan for at least the next twelve months from the date of this filing. </p> <p style="margin-top:12pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">However, if the Company’s anticipated operating results are not achieved in future periods, management believes that planned expenditures can be reduced to extend the time period over which the then-available resources would be able to fund its operations. The Company plans to continue to fund losses from operations and capital funding needs through future equity and/or debt financings, as well as potential additional asset sales, licensing transactions, collaborations or strategic partnerships with other companies. The sale of additional equity or convertible debt could result in additional dilution to its stockholders. The incurrence of indebtedness would result in debt service obligations and could result in operating and financing covenants that would restrict the Company’s operations. The Company can provide no assurance that financing will be available in the amounts it needs or on terms acceptable to it, if at all. If the Company is not able to secure adequate additional funding it may be forced to delay, make reductions in spending, extend payment terms with suppliers, liquidate assets where possible, and/or suspend or curtail planned programs. Any of these actions could materially harm its business.</p></div> | |
| CY2016 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
635000 | |
| CY2016 | us-gaap |
Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
|
2231000 | |
| CY2016 | us-gaap |
Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
|
99000 | |
| CY2016 | us-gaap |
Derivative Gain Loss On Derivative Net
DerivativeGainLossOnDerivativeNet
|
1057000 | |
| CY2016 | us-gaap |
Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
|
-461000 | |
| CY2016 | us-gaap |
Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
|
-400000 | |
| CY2016 | us-gaap |
Increase Decrease In Prepaid Rent
IncreaseDecreaseInPrepaidRent
|
19000 | |
| CY2017 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-19940000 | |
| CY2016 | us-gaap |
Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
|
-18472000 | |
| CY2017 | us-gaap |
Payments To Acquire Investments
PaymentsToAcquireInvestments
|
25472000 | |
| CY2016 | us-gaap |
Payments To Acquire Investments
PaymentsToAcquireInvestments
|
13401000 | |
| CY2016 | us-gaap |
Proceeds From Sale Of Productive Assets
ProceedsFromSaleOfProductiveAssets
|
1674000 | |
| CY2017 | us-gaap |
Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
|
57000 | |
| CY2016 | us-gaap |
Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
|
5000 | |
| CY2016 | us-gaap |
Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
|
890000 | |
| CY2017 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
23000 | |
| CY2016 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
468000 | |
| CY2017 | us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-11252000 | |
| CY2016 | us-gaap |
Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
|
-1308000 | |
| CY2017 | us-gaap |
Proceeds From Repayments Of Restricted Cash Financing Activities
ProceedsFromRepaymentsOfRestrictedCashFinancingActivities
|
14318000 | |
| CY2016 | us-gaap |
Proceeds From Repayments Of Restricted Cash Financing Activities
ProceedsFromRepaymentsOfRestrictedCashFinancingActivities
|
14330000 | |
| CY2017 | us-gaap |
Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
|
14318000 | |
| CY2016 | us-gaap |
Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
|
14340000 | |
| CY2017 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
5336000 | |
| CY2016 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
958000 | |
| CY2017 | cbio |
Proceeds From Issuance Of Preferred Stock Common Stock And Warrants For Follow On Offering Net Of Issuance Costs
ProceedsFromIssuanceOfPreferredStockCommonStockAndWarrantsForFollowOnOfferingNetOfIssuanceCosts
|
18563000 | |
| CY2017 | us-gaap |
Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
|
1817000 | |
| CY2017 | us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
35400000 | |
| CY2016 | us-gaap |
Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
|
948000 | |
| CY2017 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
4208000 | |
| CY2016 | us-gaap |
Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
|
-18832000 | |
| CY2015Q4 | us-gaap |
Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
|
29096000 | |
| CY2017 | cbio |
Noncash Or Part Noncash Deemed Dividend For Convertible Preferred Stock Beneficial Conversion Feature
NoncashOrPartNoncashDeemedDividendForConvertiblePreferredStockBeneficialConversionFeature
|
3951000 | |
| CY2017 | cbio |
Noncash Or Part Noncash Unrealized Gain Loss On Investments
NoncashOrPartNoncashUnrealizedGainLossOnInvestments
|
1000 | |
| CY2017 | us-gaap |
Increase Decrease In Deposit Other Assets
IncreaseDecreaseInDepositOtherAssets
|
128000 | |
| CY2017 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<div> <p style="margin-top:18pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-top:6pt;margin-bottom:0pt;margin-left:5.24%;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. On an ongoing basis, management evaluates its estimates, including those related to revenue recognition, convertible notes and related warrants up to the date of conversion, common stock and stock-based compensation. The Company bases its estimates on various assumptions that the Company believes to be reasonable under the circumstances. Actual results could differ from those estimates.</p></div> | |
| CY2017Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
|
13.69 | |
| CY2015 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
|
P5Y6M3D | |
| CY2017 | us-gaap |
Number Of Operating Segments
NumberOfOperatingSegments
|
1 | |
| CY2017Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
|
45.34 | |
| CY2017Q4 | us-gaap |
Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
|
32400000 | |
| CY2017 | cbio |
Reduction To Research And Development Expense
ReductionToResearchAndDevelopmentExpense
|
100000 | |
| CY2016 | cbio |
Reduction To Research And Development Expense
ReductionToResearchAndDevelopmentExpense
|
100000 | |
| CY2017Q4 | us-gaap |
Assets Fair Value Disclosure
AssetsFairValueDisclosure
|
37638000 | |
| CY2016Q4 | us-gaap |
Assets Fair Value Disclosure
AssetsFairValueDisclosure
|
36549000 | |
| CY2017Q4 | us-gaap |
Available For Sale Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
3000 | |
| CY2017Q4 | us-gaap |
Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
3000 | |
| CY2017Q4 | us-gaap |
Available For Sale Securities
AvailableForSaleSecurities
|
37638000 | |
| CY2016Q4 | us-gaap |
Available For Sale Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
2000 | |
| CY2016Q4 | us-gaap |
Available For Sale Securities
AvailableForSaleSecurities
|
36549000 | |
| CY2017 | us-gaap |
Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
|
0 | |
| CY2017Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
2299000 | |
| CY2016Q4 | us-gaap |
Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
|
2304000 | |
| CY2017Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
2023000 | |
| CY2016Q4 | us-gaap |
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
|
1860000 | |
| CY2017 | us-gaap |
Depreciation
Depreciation
|
200000 | |
| CY2016 | us-gaap |
Depreciation
Depreciation
|
400000 | |
| CY2017 | us-gaap |
Restructuring Charges
RestructuringCharges
|
0 | |
| CY2017 | us-gaap |
Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
|
0 | |
| CY2017 | cbio |
Operating Lease Expiration Date
OperatingLeaseExpirationDate
|
2018-02 | |
| CY2017 | us-gaap |
Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
|
800000 | |
| CY2016 | us-gaap |
Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
|
700000 | |
| CY2017Q4 | us-gaap |
Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
|
475000 | |
| CY2017Q4 | us-gaap |
Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
|
489000 | |
| CY2017Q4 | us-gaap |
Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
|
500000 | |
| CY2017Q4 | us-gaap |
Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
|
511000 | |
| CY2017Q4 | us-gaap |
Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
|
523000 | |
| CY2017Q4 | cbio |
Operating Leases Future Minimum Payments Due In Six Years
OperatingLeasesFutureMinimumPaymentsDueInSixYears
|
155000 | |
| CY2017Q4 | us-gaap |
Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
|
2653000 | |
| CY2013 | cbio |
License Fees Payable
LicenseFeesPayable
|
100000 | |
| CY2017 | us-gaap |
Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
|
0 | |
| CY2015Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
146634 | |
| CY2016 | cbio |
Aggregate Fractional Shares Written Off Upon Conversion Of Options Assumed In Merger
AggregateFractionalSharesWrittenOffUponConversionOfOptionsAssumedInMerger
|
4 | |
| CY2016 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
|
13773 | |
| CY2016 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
|
6573 | |
| CY2017 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
|
141 | |
| CY2017Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
821741 | |
| CY2017Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
|
161240 | |
| CY2017Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
|
821741 | |
| CY2016 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
|
259.05 | |
| CY2016Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
128.25 | |
| CY2017 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
4.56 | |
| CY2017 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
|
41.91 | |
| CY2017 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
|
165.63 | |
| CY2017Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
13.69 | |
| CY2015Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
16000 | |
| CY2017Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
|
6376000 | |
| CY2017 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
863000 | |
| CY2017Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
|
821741 | |
| CY2017 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.3400 | |
| CY2016 | us-gaap |
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
|
0.3400 | |
| CY2017 | us-gaap |
Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
|
0.0000 | |
| CY2016 | us-gaap |
Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
|
0.0112 | |
| CY2017 | cbio |
Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
|
-0.0060 | |
| CY2016 | cbio |
Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
|
0.0795 | |
| CY2017 | us-gaap |
Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
|
0.0164 | |
| CY2016 | us-gaap |
Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
|
0.0316 | |
| CY2017 | cbio |
Effective Income Tax Rate Reconciliation Derecognition
EffectiveIncomeTaxRateReconciliationDerecognition
|
-0.5408 | |
| CY2016 | cbio |
Effective Income Tax Rate Reconciliation Derecognition
EffectiveIncomeTaxRateReconciliationDerecognition
|
0.0000 | |
| CY2017 | us-gaap |
Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
0.5290 | |
| CY2016 | us-gaap |
Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
-0.4666 | |
| CY2017 | us-gaap |
Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
|
-0.3389 | |
| CY2016 | us-gaap |
Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
|
0.0000 | |
| CY2017 | us-gaap |
Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
|
0.0003 | |
| CY2016 | us-gaap |
Effective Income Tax Rate Reconciliation Nondeductible Expense Other
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther
|
0.0043 | |
| CY2017Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
|
1112000 | |
| CY2016Q4 | us-gaap |
Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
|
1137000 | |
| CY2017Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
11519000 | |
| CY2016Q4 | us-gaap |
Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
|
25944000 | |
| CY2017Q4 | us-gaap |
Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
|
3545000 | |
| CY2016Q4 | us-gaap |
Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
|
3174000 | |
| CY2017Q4 | cbio |
Deferred Tax Assets Fixed Assets And Intangibles
DeferredTaxAssetsFixedAssetsAndIntangibles
|
89000 | |
| CY2016Q4 | cbio |
Deferred Tax Assets Fixed Assets And Intangibles
DeferredTaxAssetsFixedAssetsAndIntangibles
|
114000 | |
| CY2017Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
16265000 | |
| CY2016Q4 | us-gaap |
Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
|
30369000 | |
| CY2017 | cbio |
Research And Development Tax Credit Carry Forwards Derecognized
ResearchAndDevelopmentTaxCreditCarryForwardsDerecognized
|
6100000 | |
| CY2017Q4 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
1475000 | |
| CY2015Q4 | us-gaap |
Unrecognized Tax Benefits
UnrecognizedTaxBenefits
|
1314000 | |
| CY2016 | cbio |
Unrecognized Tax Benefits Increase Decrease Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions
|
6000 | |
| CY2016 | us-gaap |
Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
|
219000 | |
| CY2017 | cbio |
Unrecognized Tax Benefits Increase Decrease Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions
|
-126000 | |
| CY2017 | us-gaap |
Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
|
62000 | |
| CY2017Q4 | us-gaap |
Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
|
0 | |
| CY2016Q4 | us-gaap |
Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
|
0 | |
| CY2017 | us-gaap |
Income Tax Reconciliation Change In Enacted Tax Rate
IncomeTaxReconciliationChangeInEnactedTaxRate
|
7300000 | |
| CY2017 | us-gaap |
Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
|
7300000 | |
| CY2017 | cbio |
Tax Cuts And Jobs Act Of2017 Change In Tax Rate Income Tax Expense Benefit
TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit
|
0 | |
| CY2016 | cbio |
Change In Derivative Liability
ChangeInDerivativeLiability
|
1156000 | |
| CY2017 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
261000 | |
| CY2016 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
86000 | |
| CY2017Q2 | us-gaap |
Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
|
2070000 | |
| CY2017Q2 | us-gaap |
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
|
5.50 | |
| CY2017Q2 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
18600000 | |
| CY2017Q2 | us-gaap |
Share Price
SharePrice
|
5.28 | |
| CY2017Q2 | us-gaap |
Proceeds From Issuance Of Warrants
ProceedsFromIssuanceOfWarrants
|
5000000 | |
| CY2016Q4 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
12039 | |
| CY2017 | cbio |
Class Of Warrant Or Right Warrants Issued During Period
ClassOfWarrantOrRightWarrantsIssuedDuringPeriod
|
2070000 | |
| CY2017 | cbio |
Class Of Warrant Or Right Exercised During Period
ClassOfWarrantOrRightExercisedDuringPeriod
|
-330331 | |
| CY2017Q4 | us-gaap |
Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
|
1751708 | |
| CY2016Q4 | us-gaap |
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
|
145.11 | |
| CY2017 | cbio |
Class Of Warrant Or Right Exercise Price Per Warrant Or Right Issued
ClassOfWarrantOrRightExercisePricePerWarrantOrRightIssued
|
5.50 | |
| CY2017 | cbio |
Class Of Warrant Or Right Exercise Price Per Warrants Or Right Exercised
ClassOfWarrantOrRightExercisePricePerWarrantsOrRightExercised
|
5.50 | |
| CY2017Q4 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
9700000 | |
| CY2017 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
3346332 | |
| CY2016 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
293796 |
